The key challenge is determining whether this represents a true drug-related risk or reflects confounding factors among patients who are more likely to receive semaglutide
Documentation for building strong cases encompasses the following elements: Prescription history showing Ozempic dosage, duration, and prescribing indication (diabetes versus weight loss) Emergency department records detailing acute symptom presentation and treatment Hospitalization records demonstrating severity through admission duration, IV hydration, nutritional support Diagnostic test results including gastric emptying studies, upper endoscopy ruling out obstruction, CT scans Gastroenterologist consultation notes confirming gastroparesis diagnosis Ongoing treatment records showing persistent symptoms and quality of life impacts Documentation of work absences, disability claims, or lifestyle modifications necessitated by symptoms Certain factors may disqualify or weaken potential claims, making early case evaluation
Even if both are the same concentration, combining them introduces unnecessary contamination risk and makes tracking the 28-day expiration window impossible
While human studies on semaglutide during pregnancy are limited, animal studies suggest an increased risk of miscarriage and birth defects
